# Anji Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/anji-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.anjipharma.com
- Total disclosed funding: $26M
- Latest round: Series A (Sep 16, 2020)
- Investors on record: 1

## About

Based in Shanghai, China, and established in 2018, Anji Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the R&D of innovative drugs for metabolic diseases. The company's CEO, Ph.D. Brian Hubbard, has over 20 years of biopharmaceutical experience at Millennium Pharmaceuticals, Novartis, and Merck. Also, the company has additional offices in the USA.

The company developed candidate drugs for chronic kidney disease and chronic constipation. The company's products pipelines include ANJ900 Metformin DR, ANJ908 Pradigastat, ANJ810 MCL1 Inhibitor and ANJ114 HCK Inhibitor. ANJ900 Metformin DR is designed for gut-targeted delivery of metformin and is in Phase 3 clinical trials for Type 2 diabetes (T2D) patients with moderate renal impairment. ANJ908 Pradigastat is in Phase 2 clinical trials to treat chronic idiopathic constipation. The ANJ810 MCL1 Inhibitor can specific killing cancer cells in preclinical models. ANJ114 HCK Inhibitor can treat myeloid leukemia.

## Funding rounds

- Series A, Sep 16, 2020, $12M — Viva Ventures Biotech
- Series A, Jun 28, 2019, $14M — Viva Ventures Biotech

## Investors

- Viva Ventures Biotech (https://capitalatlas.ai/funds/viva-ventures-biotech) — Series A